Conjugates of a novel 7-substituted camptothecin with RGD-peptides as α(v)β₃ integrin ligands: An approach to tumor-targeted therapy

Bioconjug Chem. 2010 Nov 17;21(11):1956-67. doi: 10.1021/bc100097r. Epub 2010 Oct 15.

Abstract

Eight conjugates of a novel camptothecin derivative (Namitecan, NMT) with RGD peptides have been synthesized and biologically evaluated. This study focused on factors that optimize the drug linkage to the transport vector. The different linkages investigated consist of heterofunctional glycol fragments and a lysosomally cleavable peptide. The linkage length and conformation were systematically modified with the purpose to understand their effect on receptor affinity, systemic stability, cytotoxicity, and solubility of the corresponding conjugates. Among the new conjugates prepared, C6 and C7 showed high receptor affinity and tumor cell adhesion, acceptable stability in murine blood, and high cytotoxic activity (IC₅₀ = 8 nM). The rationale, synthetic strategy, and preliminary biological results will be presented.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / blood
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacology*
  • Camptothecin / analogs & derivatives*
  • Camptothecin / blood
  • Camptothecin / chemistry
  • Camptothecin / pharmacology
  • Cell Proliferation / drug effects
  • Drug Screening Assays, Antitumor
  • Humans
  • Integrin alphaVbeta3 / metabolism*
  • Ligands
  • Mice
  • Molecular Conformation
  • Oligopeptides / blood
  • Oligopeptides / chemistry*
  • Oligopeptides / metabolism*
  • Stereoisomerism
  • Structure-Activity Relationship
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Integrin alphaVbeta3
  • Ligands
  • Oligopeptides
  • arginyl-glycyl-aspartic acid
  • namitecan
  • Camptothecin